InnovaResistance: Innovative approaches to address antibacterial resistance
The dearth of new bactericidal or bacteriostatic drugs entering the clinic and the emergence of infections due to multi-antibiotic resistant bacteria requires international collaboration supported by substantial financial investment. New drugs and/or therapeutic approaches are urgently needed to control bacterial infections and safeguard the health of populations.
The primary aim of this first joint call of JPIAMR is to combine the resources, infrastructures, and research strengths of multiple countries in order to overcome antibiotic resistance. The goal is to foster multinational translational research collaborations that can accomplish more than individual countries working independently, leading to improved control of bacterial infections.
It is expected that through international collaborations that combine complementary and synergistic research strengths, this JPIAMR call will facilitate the generation and application of new approaches to overcome antibiotic resistance.
The call will cover research addressing the following topics:
• Re-evaluation of existing anti-microbial compounds either alone or in combination with other drugs, immune-
modulators or anti-bacterial approaches.
• Identification of new bacterial targets and/or therapeutic compounds in combination with point-of-care
companion diagnostics where relevant.
• Discovery and implementation of novel therapies to overcome known antimicrobial resistance mechanisms
and restore susceptibility to conventional antibiotics. Examples might include studies on novel enzyme or
efflux pump inhibitors, as well as studies aimed at understanding and overcoming the mechanisms
controlling the generation of resistance.
• Strategies for optimization of drug use, dosage and delivery of new drugs or drug combinations.
• Strategies to inhibit or reduce the acquisition of resistance such as single molecular agents effective against
multiple targets as well as therapeutics that enhance immune pathogen elimination, disrupt colonization,
biofilm development, and virulence.
Following sub-topics are not in the purpose of the call:
• Assessing the role of commensal flora in homeostasis and microbe’s pathogenicity, and elucidating how
commensal organisms or probiotics can be used to prevent or treat infections.
• Investigating the initial steps of the infection process.
• Late stage clinical trials (Phase II and further).
Proposals are expected to clearly define described targets and milestones to deliver clinically relevant outcomes within the funding period (maximum 3 years).
Applicants must adhere to the specific regulations of the national funding organisations and it is highly recommended for applicants to contact their national contact person (see left hand margin link) prior to submitting. Each transnational consortium submitting a proposal must involve:
• a minimum of three (3) eligible participants from three different countries participating in the call.
• a maximum of six (6) project participants from three (3) to six (6) countries.
• Project participants not eligible to be funded (e.g. from non-funding countries or not fundable according to
national/regional regulations of the participating funding countries may be involved in projects if they secure
their own funding and if their expertise is indispensable for reaching the objectives. The consortia should
always consist of a majority of funded project participants.
• Project participants not eligible to be funded cannot be consortium coordinators and must accept all JPIAMR
rules and guidelines just as funded members.
Submissions of proposals will be in two steps. In both cases, one joint proposal document (in English) shall be prepared by the project participants of a joint transnational proposal, and must be submitted to the Joint Call Secretariat by the coordinator using the online submission tool (link at the top of the page). For details see also the Guidelines for Applicants document, available in the submission tool.
Participating JPIAMR countries and anticipated funding
|Praticipating country||Organization||Million EUR|
|Belgium||FWO + FNRS||0,15+0,2
|Canada||Canadian Institute of Health Research||4,1|
|Denmark||The Danish Council for Strategic Research||0,5|
|France||Agence Nationale de la Recherche||1|
|Israel||Chief Scientist Office, Ministry of Health||0,12|
|Norway||The Research Council of Norway||0,5|
|Poland||National Centre for Research and Development||0,25|
|Spain||Instituto de Salud Carlos III||0,2|
|Sweden||Swedish Research Council+Vinnova||3+1,1|
For general questions about the call and the online submission, please contact the Joint Call Secretariat(contact info in the left hand margin). For eligibility questions and other country-specific queries, please contact your national contact person (contact info in the left hand margin).